RAMP1 and migraine disorder: Recently, in a retrospective cohort of 199 migraine patients treated with different anti-CGRP monoclonal antibodies, of which 51.7% of patients were treated with ERE, a nominal association was found between RAMP1 rs12615320 and non-responder status as assessed by the MIDAS question A [26].